- The FDA designates Biota Pharmaceuticals' (BOTA +10.6%) antiviral candidate, BTA585, for Fast Track review for the treatment of respiratory syncytial virus (RSV) infections. RSV is a major cause of upper and lower respiratory tract infections in infants, children and young adults.
- BTA585 is an oral RSV fusion inhibitor that fights RSV infection by interfering with the fusion of the viral envelope to the cell membrane of the host cell.
- Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).